I mean, how could only two thirds of the data that went to the IVUS lab end up being interpretable unless it was stacking up somewhere and not being read until the end of the trial?
DR. RUSSELL: I’m going to have Dr. Weissman answer that question, but it is one of the complexities of paired IVUS analysis. DR. WEISSMAN: I’m Neil Weissman. I’m a cardiologist from Washington Hospital Center. I directed the Core Lab. In terms of conflicts, I’m a full-time, salaried employee of MedStar Research Institute. Boston Scientific gave a grant to MedStar Research Institute to do this. No stock or anything like that. If you look at the compliance with the IVUS, it actually was very good. It’s about 75 percent, which is pretty typical for U.S. multi-center studies. What you’re looking at is how many patients had full, 3D volumetric analysis. In order to have that, they had to have every single millimeter throughout the stent visualized and the interface was visualized. DR. WHITE: But let me just stop you because it does say 2D, two dimensional analysis. In the next sentence it’s 53 percent for 3D. DR. WEISSMAN: Okay, but the cutoffs even with 2D, okay, we would go through. If yo
